A peptide that raises growth hormone. Not approved in the EU or US. We have not graded the studies yet. The number of papers in the databases is shown on the page.

PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.

Short entry. It holds facts from official registers, with no study grade. We are still writing the full description.

GHRP-6

growth hormone-releasing peptide 6

A peptide that raises growth hormone. Not approved in the EU or US.

This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.

Type: Raises growth hormone
Stage: Still being studied
Safety: Little data
Doping: Banned in sport, WADA 2026
Risk of fakes: High
Checked: Not yet

Safety. In people it was given mainly once, as a test for a shortage of growth hormone. We found no data on longer use. Sources: study 1.

Risk of fakes. An altered black-market version, Gly-GHRP-6, has turned up. Sources: study 1.

Is it legal

Where	Status		Checked
PL	No approval	The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source	Not yet
EU	No approval	The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source	Not yet
US	No approval	The FDA drug register has no such medicine. Source	Not yet

How much research exists

Scientific papers: 674
Studies with random groups: 21
Registered studies in people: 0

Scientific papers per year 2015–2025

These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.

Reported side effects

What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.

Reports to the FDA (USA)

Reports: 0
Of these, serious: 0

The FDA has no reports. That is not a sign of safety: almost nobody reports substances from outside pharmacies.

Cases described in medical journals

In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.J Endocrinol Invest 2007

FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.

More papers we found

Studies	Kind of study	Year
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.J Clin Neurosci	Random groups	2026
Insulinotropic action of bombesin-like peptides mediated by gastrin-releasing peptide receptors in steers.J Anim Sci	Random groups	2016
Bombesin-like peptides stimulate growth hormone secretion mediated by the gastrin-releasing peptide receptor in cattle.Peptides	Random groups	2012
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.Metabolism	Random groups	2010
Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).Clin Endocrinol (Oxf)	Random groups	2010
Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.Pituitary	Random groups	2007
GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.J Endocrinol Invest	Random groups	2003
Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.Mol Cell Endocrinol	Random groups	2002

We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.

All papers and studies we found (227)

Short answers

Does GHRP-6 work?: A peptide that raises growth hormone. Not approved in the EU or US. We have not graded the studies yet. The number of papers in the databases is shown on the page.
Is GHRP-6 legal?: PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.
Is GHRP-6 banned in sport?: Banned in sport, WADA 2026.
Is GHRP-6 safe?: Little data. In people it was given mainly once, as a test for a shortage of growth hormone. We found no data on longer use.

Plain text for machines